Q-omics provides the consensus-scored C3orf86 profile across patient tissues and cancer cell-line models. C3orf86 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, C3orf86 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, C3orf86 RNA expression shows 14,339 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRP, and LSCC as cancer lineages where C3orf86 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C3orf86 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C3orf86 survival associations across molecular data types. C3orf86 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C3orf86 RNA expression–survival associations across cancer types. High C3orf86 expression shows unfavorable associations in CHOL and BLCA, but favorable associations in HNSC, THCA, MESO and SARC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for C3orf86 RNA expression.
This table summarizes C3orf86 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for C3orf86. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C3orf86 shows lower tumor expression in KIRP, BLCA, KIRC, KICH, LUAD and COAD. The KIRP box plot shows higher C3orf86 RNA expression in normal versus tumor tissue (log2 FC = −1.562, t-test p < 0.001).
This table shows molecular features associated with C3orf86 in patient tissues and cancer cell lines. In patient samples, C3orf86 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
